Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H32O3 |
Molecular Weight | 332.477 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)\C(C[C@]4(C)[C@H]3CC[C@]12C)=C/O
InChI
InChIKey=ICMWWNHDUZJFDW-DHODBPELSA-N
InChI=1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1
Oxymetholone (17beta-hydroxy-2-[hydroxymethylene]-17-methyl-5alpha-androstan-3-one) is a 17alpha-alkylated anabolic-androgenic steroid and a synthetic derivative of testosterone. It has been approved by the US Food and Drug Administration for the treatment of anemias caused by deficient red cell production. Acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond. Drug interactions exist with cimetidine, paroxetine, and haloperidol, but are not expected with indinavir, ritonavir, clarithromycin, or itraconazole.
CNS Activity
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. | 1972 Dec 16 |
|
Carcinoma of the breast. Occurence after treatment with melphalan for multiple myeloma. | 1976 Oct 4 |
|
Poststeroid balance disorder--a case report in a body builder. | 1999 Aug |
|
Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. | 2001 Jun |
|
Characterization of spontaneous and chemically induced cardiac lesions in rodent model systems: the national toxicology program experience. | 2005 |
|
Oxymetholone ameliorates insulin sensitivity in maintenance hemodialysis patients: a randomized controlled trial. | 2009 Apr |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs. | 2015 Jun |
Patents
Sample Use Guides
The recommended daily dose in children and adults is 1-5 mg/kg of body weight per day. The usual effective dose is 1-2 mg/kg/day but higher doses may be required, and the dose should be individualized. Response is not often immediate, and a minimum trial of three to six months should be given. Following remission, some patients may be maintained without the drug; others may be maintained on an established lower daily dosage. A continued maintenance dose is usually necessary in patients with congenital aplastic anemia.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C243
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
||
|
DEA NO. |
4000
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
||
|
WHO-VATC |
QA14AA05
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
||
|
LIVERTOX |
727
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
||
|
WHO-ATC |
A14AA05
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
||
|
NCI_THESAURUS |
C2360
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1200585
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
PRIMARY | |||
|
D010110
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
PRIMARY | |||
|
434-07-1
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
PRIMARY | |||
|
78964-17-7
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
ALTERNATIVE | |||
|
OXYMETHOLONE
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
PRIMARY | |||
|
C723
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
PRIMARY | |||
|
7813
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
PRIMARY | RxNorm | ||
|
SUB09568MIG
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
PRIMARY | |||
|
5281034
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
PRIMARY | |||
|
1022
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
PRIMARY | |||
|
M8336
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
PRIMARY | Merck Index | ||
|
DB06412
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
PRIMARY | |||
|
434-07-1
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
PRIMARY | |||
|
434-07-1
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
PRIMARY | |||
|
207-098-6
Created by
admin on Mon Oct 21 20:38:42 UTC 2019 , Edited by admin on Mon Oct 21 20:38:42 UTC 2019
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)